DailyIQ
Last updatedjust now

IDXX·IDEXX Laboratories, Inc.

$520.23
-3.71 (-0.71%)
Overnight$520.29+0.06 (+0.01%)
High
$528.49
Open
$525.73
Market Cap
41.28B
52W High
$776.57
Low
$514.72
P. Close
$520.23
P/E
36.22
52W Low
$500.61
Fwd P/E
31.11
DailyIQ Est.
$726.40
Inst. Ownership
43.5%
Short Interest
2.45%
Days to Cover
3.9
Technical Score (1D)
20
BEARISH
News Sentiment
58
BULLISH
The 1D read on IDEXX Laboratories, Inc. (IDXX) is SELL at 20, a bottom-ranked momentum score. The stock has trailed most of the universe over the past year, excluding the latest month, and the bearish trend bias reflects that. Sentiment at 58 is diverging from the technical picture, which matters because sentiment can turn faster than a 12-month momentum rank. $499.48 is the level to hold; $541.10 is the first hurdle on any rebound. A bottom momentum rank reflects the prior year of trading, so it changes gradually even when the stock has a strong week. For near-term direction, price levels give the earlier read: a close back above $541.10 on real volume would be the first sign of repair, while a break of $499.48 keeps the bearish trend in charge.
LOW TARGET
$470 -9.7%
2 analysts
MEAN TARGET
$701 +34.8%
13 analysts
HIGH TARGET
$805 +54.7%
9 analysts
PRICE RANGE
$470.00 - $805.00
SB / B / H / S / SS
7/7/8/1/1
DAILYIQ EST.
$726.40 (+39.6%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NMS
Country
United States
Website
Symbol
IDXX
Description
IDEXX Laboratories is a global provider of diagnostic and information technology solutions for the animal health and water testing industries. The company's core business revolves around developing and distributing in-clinic diagnostic instruments, rapid assay tests, and reference laboratory services for companion animals, primarily cats and dogs. IDEXX also offers a suite of products for livestock and poultry health management, alongside water quality testing solutions designed to detect contaminants. Through its diverse offerings, IDEXX aims to improve animal health outcomes and provide critical data for water safety, with distribution facilitated by dedicated sales and service teams, as well as independent distributors. Founded in 1983, IDEXX is headquartered in Westbrook, Maine.
Bought (1Y)
0 shares
$0
Sold (1Y)
2,573 shares
$1.3M
Kingsley Lawrence D-
Option Exercise2,203 shares2026-09-04
Kingsley Lawrence D-
Sell2,203 shares2026-09-04
Kingsley Lawrence D-
Option Exercise2,203 shares2026-09-04
Emerson AndrewEVP, CFO and Treasurer
Option Exercise265 shares2026-08-20
Emerson AndrewEVP, CFO and Treasurer
Tax Withholding86 shares2026-08-20
83/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
61.8%
Net Margin
24.6%
Revenue CAGR
8.8%
Current Ratio
1.23x
Debt / Equity
0.28x
Return on Equity
66.0%
Earnings Summary
IDEXX Laboratories, headquartered in Westbrook, Maine, is a global provider of diagnostic and information technology solutions for animal health and water testing, focusing on in‑clinic instruments, rapid assays, and reference laboratory services for companion animals, livestock, and water quality. Operating within the healthcare diagnostics sector, the company leverages a diversified product mix to support veterinary and environmental monitoring markets. In the most recent quarters, IDEXX posted EPS of $2.62 in Q4 2024, $2.96 in Q1 2025, $3.63 in Q2 2025, and $3.40 in Q3 2025, each exceeding analyst expectations (2.40424, 2.84846, 3.29981, 3.13978 respectively). Revenue grew from $954.3 million in Q4 2024 to $1.109 billion in Q3 2025, a 16.5% YoY increase, and continued upward momentum into Q1 2026 with $1.140 billion, though the company missed its $1.198 billion revenue estimate. The company has consistently beat EPS estimates in the last four quarters while revenue growth has remained robust, with a 10–15% organic target cited in recent guidance. Historically, IDEXX has maintained a steady YoY revenue trajectory, with EPS growth outpacing revenue in several periods, indicating improving profitability margins. Recent news highlights the acquisition of CoVetAI, an AI‑powered clinical scribe platform, and the launch of new diagnostic products such as digital pathology and rapid testing platforms, underscoring a strategic push into AI and product innovation.

EPS

EstBeatMiss
$2.80$3.21$3.63$4.05$4.46Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.70 - -
Q2'26$3.93$4.27+8.5%
Q1'26$3.92$3.47-11.6%
Q4'25$2.99$3.08+3.1%
Q3'25$3.14$3.40+8.3%
Q2'25$3.30$3.63+10.0%

Revenue

EstBeatMiss
$1.1B$1.1B$1.2B$1.2B$1.2BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.2B - -
Q2'26$1.2B$1.2B-0.7%
Q1'26$1.2B$1.1B-4.8%
Q4'25$1.1B$1.1B-0.3%
Q3'25 - $1.1B -
Q2'25 - $1.1B -

Market Data

IDXX Stock Snapshot

BEARISH20/100
$520.29+$0.06 (0.0%)
Market cap
41.28B
P/E ratio
36.2
Day range
$514.72 – $528.49
News sentiment
58/100 · Neutral
Analyst target
$701.33 (+34.8%)
Consensus
Hold · 24 analysts
52-week range+3.9% off low · -33.0% from high
$500.61$776.57
Price $520.29 DailyIQ Est. $726.40

The chart on IDXX has not stabilised: price is near its 52-week low and the trend is still down. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into IDXX?

RICH

At today's price, IDEXX Laboratories, Inc. needs to grow free cash flow about 28.7% a year for the next 10 years to justify its valuation at a 9.74% cost of capital. Over its actual history it has compounded free cash flow at 15.1% a year, so the market is asking for 13.6 percentage points above its own delivered rate. On that basis IDXX looks priced above what its own growth record supports.

Implied FCF growth
28.7%
Historical FCF CAGR
15.1%
Growth gap
+13.6 pts
Verdict
RICH
Discount rate (WACC)
9.74%
Beta
0.91

Behaviour On Record

What IDXX's own history says about today's numbers

Realized volatility (21d)
21.7% 34th pct
Below its peak
-32.1%
vs 200-day average
-10.7%
Up days (1y)
49%

IDEXX Laboratories, Inc. is currently running 21.7% annualised volatility over the last 21 sessions. Measured against IDXX's own 13 years of daily returns rather than a market-wide average, that is the 34th percentile — on the quiet side for this stock, against a typical reading of 26.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

IDXX is trading -32.1% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -24.2%, and the deepest was -48.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -10.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 13th percentile — a narrower gap than it typically runs. Over the past year IDXX closed higher on 49% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, IDXX finished the month higher 8 of 13 times, with a median return of +2.6% and an average of +0.4%. Its strongest month historically has been July at +5.8% on average, its weakest September at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: IDXX has opened more than 2% away from the prior close in 118 of 3,267 sessions (3.6% of the time), with the largest gaps running +5.4% and -9.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, IDXX moved an average of 1.8% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.9% and a largest of +3.2%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against IDXX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of IDXX's sector?

IDEXX Laboratories, Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
82

Options Market

What is the options market pricing for IDXX?

CallsPuts

For IDEXX Laboratories, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.60).

Put/call ratio (2026-10-16)
0.60
Total open interest
990

Analyst Rating Changes

Are analysts turning bullish or bearish on IDXX?

Keybanc most recently initiated coverage on IDEXX Laboratories, Inc. to Sector Weight on Oct 12, 2026. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Keybanc — Sector Weight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026KeybancInitiatedSector Weight-
Aug 11, 2026BarclaysMaintainedOverweight$800 → $710
Aug 5, 2026UBSMaintainedNeutral$620 → $670
Aug 5, 2026CitigroupMaintainedNeutral$650 → $670
Jul 27, 2026UBSMaintainedNeutral$640 → $620
Apr 28, 2026UBSMaintainedNeutral$730 → $640
Apr 15, 2026CitigroupInitiatedNeutral$650
Mar 31, 2026StifelMaintainedBuy$775 → $675
Feb 9, 2026Piper SandlerMaintainedNeutral$775 → $750
Feb 5, 2026BarclaysMaintainedOverweight$850 → $800
Feb 3, 2026UBSMaintainedNeutral$750 → $730
Feb 3, 2026BTIGMaintainedBuy$830 → $800

Peers & ETF holders

IDXX peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

58/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
KeyBanc Securities announced a sector‑weight rating for IDEXX Laboratories, indicating a positive outlook for the company. The brokerage highlighted IDEXX’s strong market position in veterinary diagnostics and its robust earnings trajectory. The rating upgrade reflects confidence in the firm’s growth prospects and competitive moat within the diagnostics sector.
What did this article say?
Keybanc analyst Steve Dechert initiated coverage on IDEXX Laboratories (NASDAQ:IDXX) on October 12, assigning a Sector Weight rating. The move signals the bank’s confidence in IDEXX’s growth prospects and positions the company favorably within its industry. The coverage launch is expected to influence investor perception and may support the stock’s valuation. No immediate earnings or guidance changes were disclosed in the announcement. The coverage reflects a positive outlook for IDEXX’s future performance.
What did this article say?
IDEXX Laboratories scheduled the release of its 2026 third‑quarter financial results for Monday, November 2, 2026, ahead of the market open. The company will host an analyst conference call at 8:30 a.m. ET, with a live webcast, transcript, and earnings snapshot available on its investor website. A recorded version of the call will be archived for one year. The announcement provides investors with the timing and access details for the upcoming earnings presentation.
What did this article say?
IDEXX Laboratories announced the acquisition of CoVetAI, an AI‑powered clinical scribe and workflow platform tailored for veterinary medicine. The deal, disclosed on September 30, was completed without financial terms being made public. CoVetAI’s technology is expected to streamline veterinary clinical documentation and enhance diagnostic workflows for IDXX’s veterinary customers. The transaction represents a strategic move to broaden IDXX’s AI portfolio and deepen its presence in the veterinary diagnostics market. No immediate impact on financial guidance was reported, but the acquisition signals a commitment to expanding AI-driven solutions.
What did this article say?
IDXX Laboratories completed the acquisition of CoVetAI, a developer of AI‑powered clinical scribe and workflow solutions for veterinary medicine. The deal, announced on September 30, 2026, was the first realization for Chicago Pacific Founders Pet Fund, which had invested in CoVetAI. By integrating CoVetAI’s platform, IDXX aims to enhance its veterinary diagnostics and practice software ecosystem, reinforcing its position as a leader in companion animal care technology. The transaction underscores the growing importance of AI tools in veterinary practice and is expected to broaden IDXX’s product portfolio and market reach.
What did this article say?
IDEXX Laboratories reiterated its long‑term growth outlook while spotlighting new diagnostic products in its pipeline. The company emphasized continued investment in digital pathology and rapid testing platforms, positioning itself to capture expanding market share. Management highlighted expected revenue growth driven by both existing services and upcoming product launches, reinforcing confidence in the company’s strategic trajectory.
What did this article say?
IDXX reiterated its long‑term growth targets, aiming for over 10% organic revenue growth and more than 15% EPS expansion, driven by veterinary diagnostics demand and product innovation. The company highlighted its expanding pipeline, including broader inVue Dx FNA and a new Cancer Dx platform targeting three major canine cancers by year‑end, which could lift reference‑lab volumes. CEO Mike Erickson praised an "exceptional Q2" and announced a higher full‑year guidance, underscoring confidence in recurring revenue economics and commercial investments.
What did this article say?
IDXX announced the acquisition of CoVetAI, a veterinary software firm that records and organizes clinical conversations. The tool integrates with IDXX’s existing cloud practice platform and VetConnect PLUS, giving it immediate access to over 10,000 clinics. By providing real‑time patient data to veterinarians, the scribe is expected to increase test ordering and laboratory throughput. The purchase aligns with IDXX’s recent 10% revenue growth and 11% rise in recurring diagnostics, suggesting a strategic push to enhance workflow efficiency. The deal’s price was undisclosed, but the strategic fit and potential volume lift signal a positive catalyst for the company.
What did this article say?
IDEXX Laboratories’ share price has fallen 26% amid concerns that its current valuation may not reflect future cash flows. The company’s recent acquisition of CoVetAI adds AI‑driven veterinary software to its portfolio, potentially boosting revenue and operating efficiency, but also introduces uncertainty about the timing of cash inflows. Analysts note the 35x P/E ratio and declining 5‑year performance, suggesting investors are re‑examining the intrinsic value of the stock. The market is weighing whether the AI expansion will materially improve earnings or simply add complexity without immediate upside.
What did this article say?
IDEXX Laboratories has broadened its Faecal Dx antigen testing platform in the UK to detect taeniid tapeworms such as Taenia and Echinococcus during routine veterinary visits. The move complements the recent CoVetAI acquisition, reinforcing IDXX’s strategy to deepen its diagnostic portfolio and enhance workflow integration. While the stock has underperformed year‑to‑date, the long‑term shareholder return remains positive, indicating sustained investor confidence. The expansion is expected to generate incremental revenue and strengthen IDXX’s competitive position in veterinary diagnostics.

Technical Analysis

Real-time indicators across multiple timeframes

20
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $19.45B combined position · 16 adding, 9 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell9,945,32812.54%$6.73B2026-01-29
BlackRock, Inc.▼ Sell8,170,17810.30%$4.30B2026-08-07
Invesco Ltd.▲ Buy3,611,4164.55%$1.90B2026-08-14
Geode Capital Management, LLC▼ Sell2,562,8863.23%$1.35B2026-08-12
Morgan Stanley▲ Buy1,356,1031.71%$713.91M2026-08-13
Northern Trust Corp▲ Buy918,1371.16%$483.34M2026-08-13
FMR LLC (Fidelity)▲ Buy822,6431.04%$433.07M2026-08-13
Capital Research Global Investors▲ Buy789,1110.99%$415.47M2026-08-12
JPMorgan Chase & Co▼ Sell755,7910.95%$405.05M2026-08-12
Goldman Sachs Group Inc▲ Buy738,7080.93%$388.89M2026-08-14
Wellington Management Group LLP▼ Sell726,6950.92%$382.56M2026-08-14
Polen Capital Management LLC▼ Sell532,3840.67%$280.27M2026-08-04
Bank of America Corp▼ Sell476,9980.60%$251.11M2026-08-14
Norges Bank▼ Sell353,9440.45%$186.33M2026-08-12
Baillie Gifford & Co▲ New353,7970.45%$186.25M2026-08-06
Neuberger Berman Group LLC▲ Buy353,3220.45%$186.00M2026-08-13
Squarepoint Ops LLC▲ Buy315,1640.40%$165.91M2026-08-14
William Blair Investment Management, LLC▼ Sell298,1540.38%$156.96M2026-08-12
Point72 Asset Management, L.P.▲ Buy262,9050.33%$138.40M2026-08-14
Wells Fargo & Company▲ Buy209,0920.26%$110.07M2026-08-14
Citigroup Inc▲ Buy165,6890.21%$87.23M2026-08-03
Renaissance Technologies LLC▲ Buy109,7840.14%$57.79M2026-08-13
AllianceBernstein L.P.▲ Buy95,7730.12%$53.81M2026-08-14
Marshall Wace, LLP▲ Buy93,1280.12%$49.03M2026-08-13
Millennium Management LLC▲ Buy78,9800.10%$41.58M2026-08-14
Q2 2026 flow:3.42M sh bought ($1.80B)691.5K sh sold ($364.11M)net +2.73M sh (+$1.44B)
Congressional Trading Activity
23 disclosed trades · ~$442.5K est. traded value · 12 buys, 11 sells
MemberChamberStateTypeAmountTradedFiled
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-01-132026-02-02
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2025-12-022026-01-05
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2025-10-292025-11-04
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2025-10-162025-11-04
Byron DonaldsHouseFL19▲ Buy$1K - $15K2025-09-042025-10-07
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2025-08-072025-09-02
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2025-08-012025-09-02
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2025-07-092025-08-05
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Jefferson ShreveHouseIN06▼ Sell$100K - $250K2025-05-122025-06-22
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-04-092025-05-02
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-04-28
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-04-072025-05-02
Jefferson ShreveHouseIN06▲ Buy$50K - $100K2025-04-072025-05-08
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-04-042025-05-02
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-04-012025-05-02
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-03-142025-04-02
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-03-132025-04-11
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-01-222024-02-14
Tommy TubervilleSenateAL▲ Buy$1K - $15K2023-04-032023-05-12
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-10-052022-11-10
Tommy TubervilleSenateAL▲ Buy$1K - $15K2021-03-292021-07-23